"The AggreWell™400 plate standardizes a critical step in the development of embryonic and induced pluripotent stem cells into clinically-relevant mature cells," says Clive Glover, Ph.D., STEMCELL Technologies' Product Manager for Pluripotent Stem Cell Biology. "These cells have been difficult to work with because of the lack of standardized methods to culture and differentiate them. The AggreWell™400 plate is the latest product in STEMCELL Technologies' portfolio that addresses the need for standardized methods and tools for stem cell research."
Many protocols for inducing the development ESC and iPSC into clinically relevant cell types rely on the formation of embryoid bodies (EBs), which are 3-dimensional aggregates of cells. In addition to being labor-intensive, current methods for making EBs results in aggregates that are inconsistent in size and shape, leading to inefficient differentiation.
In contrast, researchers using the AggreWell™400 plates are able to control the size of EBs, enabling them to optimize their differentiation protocols. Additionally the AggreWell™400 plates allow stem cell scientists to easily create large quantities of uniformly-sized EBs
For more information about the AggreWell™400 plates, visit
About STEMCELL Technologies
STEMCELL Technologies, a leader in specialty cell culture media, cell separation products and ancillary reagents for stem cell research, is a privately-owned biotechnology company based in Vancouver, Canada. Driven by science, STEMCELL Technologies delivers over 800 products to more than 70 countries worldwide including mTeSR™1, a defined, feeder-independent medium for hESC and hiPSC.